Treatment for advanced non-small cell lung cancer has changed in the last two decades,
with many new drugs, mostly target agents, included in the algorithm, improvement of progression
free survival and overall survival, but also higher costs for health systems or health insurances.
Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according
to their clinically meaningful outcome criteria and their cost impact.
Keywords: NSCLC, target agents, therapy, cost, chemotherapy, metastases, prognoses.
Rights & PermissionsPrintExport